No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
- Language
-
Englisch
- Identifier
-
1169134998
Contributor
Colhoun, Helen M.
Ginsberg, Henry N.
Robinson, Jennifer G.
Leiter, Lawrence A.
Müller-Wieland, Dirk
Henry, Robert R.
Cariou, Bertrand
Baccara-Dinet, Marie T.
Pordy, Robert
Merlet, Laurence
Eckel, Robert H.
Ginsberg, Henry N.
Robinson, Jennifer G.
Leiter, Lawrence A.
Müller-Wieland, Dirk
Henry, Robert R.
Cariou, Bertrand
Baccara-Dinet, Marie T.
Pordy, Robert
Merlet, Laurence
Eckel, Robert H.
- DOI
-
10.18154/RWTH-2017-01249
- URN
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
26.01.2023, 1:52 PM CET
Associated
- Colhoun, Helen M.
- Ginsberg, Henry N.
- Robinson, Jennifer G.
- Leiter, Lawrence A.
- Müller-Wieland, Dirk
- Henry, Robert R.
- Cariou, Bertrand
- Baccara-Dinet, Marie T.
- Pordy, Robert
- Merlet, Laurence
- Eckel, Robert H.
Other Objects (12)
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk : The ODYSSEY DM-INSULIN randomized trial
Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial
Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials
Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline : a pooled analysis of 10 phase III ODYSSEY clinical trials
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease : analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies
Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
Acute disseminated encephalomyelitis following endonasal resection of a craniopharyngioma: illustrative case
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial
A single Sfp-type Phosphopantetheinyl transferase plays a major role in the biosynthesis of PKS and NRPS derived metabolites in Streptomyces ambofaciens ATCC23877
Ein Königreich für die Leidenschaft
The BrainMap strategy for standardization, sharing, and meta-analysis of neuroimaging data
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk : The ODYSSEY DM-INSULIN randomized trial
Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial
Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials
Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline : a pooled analysis of 10 phase III ODYSSEY clinical trials
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease : analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies
Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
Acute disseminated encephalomyelitis following endonasal resection of a craniopharyngioma: illustrative case
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial
A single Sfp-type Phosphopantetheinyl transferase plays a major role in the biosynthesis of PKS and NRPS derived metabolites in Streptomyces ambofaciens ATCC23877
Ein Königreich für die Leidenschaft
The BrainMap strategy for standardization, sharing, and meta-analysis of neuroimaging data
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk : The ODYSSEY DM-INSULIN randomized trial
Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial
Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials
Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline : a pooled analysis of 10 phase III ODYSSEY clinical trials
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease : analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies
Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
Acute disseminated encephalomyelitis following endonasal resection of a craniopharyngioma: illustrative case
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial
A single Sfp-type Phosphopantetheinyl transferase plays a major role in the biosynthesis of PKS and NRPS derived metabolites in Streptomyces ambofaciens ATCC23877
Ein Königreich für die Leidenschaft